About Kremoint Pharma Private Limited
Data last updated: 16 February 2026
Kremoint Pharma Private Limited is a private limited company based in Ambernath, Maharashtra, India, a subsidiary of Bliss Gvs Pharma Limited. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 12 May 1992, the company has been in operation for over 34 years.
Registered with ROC Mumbai under CIN U24230MH1992PTC066737.
Capital: an authorised share capital of ₹25 Lakh and a paid-up capital of ₹6 Lakh. It is led by directors including Vibha Gagan Sharma and Bhadresh Keshavji Thakkar.
Last AGM: 02 July 2025. Financial statements filed for year ended 31 March 2025. Office: B – 8 Additional Ambernath Midc Opp. Anand Nagar Octroi Naka, Maharashtra, India – 421506.
As per the financials filed for FY 2025, the company reported a revenue of ₹64.72 Cr, a growth of 12% compared to the previous year.
The company has a workforce of approximately 121 employees as per the latest available data. It operates as a subsidiary of Bliss Gvs Pharma Limited. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Kremoint Pharma. As per MCA filings, the company has open charges of ₹1.01 Cr and satisfied charges of ₹42.29 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website kremointpharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressB – 8 Additional Ambernath Midc Opp. Anand Nagar Octroi Naka, Maharashtra, India – 421506
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Kremoint Pharma Private Limited
Kremoint Pharma Private Limited operates one associated brand: Kremoint Pharma. These brands represent Kremoint Pharma Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Traditional pharmaceutical company manufacturing and marketing variety of finished dosage forms | kremointpharma.com |
Business Activity of Kremoint Pharma Private Limited
Kremoint Pharma Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Kremoint Pharma Private Limited
Kremoint Pharma Private Limited is audited by Panachand K Shah & Co. for the financial year 2022. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Panachand K Shah & Co. | blur-value | blur-value | blur-value |
Board of Directors of Kremoint Pharma Private Limited
Kremoint Pharma Private Limited is currently managed by 5 directors, with 7 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vibha Gagan Sharma | Director | 12 Jun 2020 | 6 Years 0 Months | Current |
| Bhadresh Keshavji Thakkar | Managing Director | 12 May 1992 | 34 Years 1 Months | Current |
|
Yesha Bhadresh Thakkar
Also directs:
Eipii Exports Private Limited
|
Director | 20 Jul 2024 | 1 Years 11 Months | Current |
|
Shruti Vishal Rao
Also directs:
Gvsk Llp, Bliss Gvs Pharma Limited
|
Director | 20 Jul 2024 | 1 Years 11 Months | Current |
| Vishal Vijay Rao | Director | 15 Jan 2025 | 1 Years 5 Months | Current |
Financials of Kremoint Pharma Private Limited FY 2025 filings available
Kremoint Pharma Private Limited reported revenue of ₹64.72 Cr (up 12% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Kremoint Pharma Private Limited
As of FY 2023, Kremoint Pharma Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Kremoint Pharma Private Limited
Kremoint Pharma Private Limited has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Kremoint Pharma Private Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Eipii Exports Private Limited | U52100MH2014PTC259675 |
**.**%
|
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Kremoint Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Jul 2023 | Others | ₹1 Lakh | Open |
| 27 May 2023 | Others | ₹1 Cr | Open |
| 08 Jan 2025 | Others | ₹4 Cr | Satisfied |
| 02 Feb 2024 | Others | ₹5 Cr | Satisfied |
| 25 Feb 2020 | Hdfc Bank Limited | ₹33.95 Lakh | Satisfied |
Total charge records: 16 View all charges
Employees and EPFO Compliance at Kremoint Pharma Private Limited
Kremoint Pharma Private Limited has a workforce of 121 employees as of Apr 04, 2024.
Employee Count & EPFO Data of Kremoint Pharma Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Kremoint Pharma Private Limited
GSTIN & GST Filing Data of Kremoint Pharma Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Kremoint Pharma Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Kremoint Pharma Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Kremoint Pharma Private Limited
MSME Payment Delays by Kremoint Pharma Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Kremoint Pharma Private Limited
Subsidiaries & Group Companies of Kremoint Pharma Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Kremoint Pharma Private Limited with ownership details.
MCA Filings & Documents of Kremoint Pharma Private Limited
MCA Filings & Documents of Kremoint Pharma Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Kremoint Pharma Private Limited
Frequently Asked Questions about Kremoint Pharma Private Limited
Kremoint Pharma Private Limited is an active private limited company in the pharma sector based in Ambernath, Maharashtra, India. It was incorporated on 12 May 1992 (34+ years old) and is registered under CIN U24230MH1992PTC066737. The company has 121 employees.
Kremoint Pharma Private Limited reported revenue of ₹64.72 Cr for FY 2025 (up 12.00% YoY).
The current directors of Kremoint Pharma Private Limited are:
The primary industry of Kremoint Pharma Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Kremoint Pharma Private Limited can be reached at the registered office: B – 8 Additional Ambernath Midc Opp. Anand Nagar Octroi Naka, Maharashtra, India – 421506, or through the website kremointpharma.com.
The authorised capital is ₹25 Lakh, and the paid-up capital is ₹6 Lakh.